SACRAMENTO, Calif., March. 17, 2017 /PRNewswire/ — Dr. Chris Yu, Ceo of worldwide existence sciences corporation Anpac Bio-Medical Science Company, announced now the organization set a brand new, worldwide record, processing and reporting 50 plus,000 cases worldwide from the company’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests.
Referred to as “game altering”, and finding the, “Breakthrough Innovation Award”, at World Nobel Prize Laureate Summit and named, “Most Promising Cancer Screening Company”, in the 2017 Global Precision Medicine Industry Awards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and recognition.
By analyzing simple, standard, bloodstream tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater precision than most up to date, conventional screening methods. Also it achieves this with no dangerous negative effects in patients generating far less “false positives” at a price substantially less than traditional testing and generating results in a few minutes of sample submission.
Comprehensive research validity data in the 50,000+ cases processed up to now demonstrate CDA diagnostics consistently identify over 26+ cancers — having a sensitivity and specificity rate selection of 75%-90% — usually identifying the condition at its earliest stages.
The organization has filed over 200 CDA-related patent applications worldwide – 65+ issued presently and maintains operations in six sites, employing over 100 people globally.
“Since our organization launched in 2008, Anpac Bio has pioneered the ‘liquid biopsy’ space,” states Dr. Yu. “Our CDA technologies have been extensively tested, verified, and used daily by a large number of Asia’s best-respected and famous medical institutions. We’re also generating equally accurate and good results in the U . s . States. So that as these studies continues to be printed and presented before respected scientific organizations, like the American Society of Clinical Oncology (ASCO) and also the World Nobel Prize Laureate Summit, our CDA exams are in great demand. We are now processing CDA tests for people, health systems, insurance providers, educational facilities, and corporations. We are very proud our CDA devices have advanced past the laboratory, and therefore are processing real tests legitimate people – saving lives every single day. Only at that rate, we project to double our CDA cases worldwide and save a lot more resides in 2018!”
To learn more about Anpac Bio book: world wide web.AnpacBio.com.
View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/anpac-bio-surpasses-50000-situation-study-milestone-liquid-biopsy-pioneer-serving-individual-medical-insurance–corporate-customers-300538549.html
SOURCE Anpac Bio-Medical Science Company
http://world wide web.AnpacBio.com